Medical expenditure for lung cancer in China: a multicenter, hospital-based retrospective survey

Abstract

Background Lung cancer is the most prevalent cancer, and the leading cause of cancer-related deaths in China. The aim of this study was to estimate the direct medical expenditure incurred for lung cancer care and analyze the trend therein for the period 2002–2011 using nationally representative data in China Methods This study was based on 10-year, multicenter retrospective expenditure data collected from hospital records, covering 15,437 lung cancer patients from 13 provinces diagnosed during the period 2002–2011. All expenditure data were adjusted to 2011 to eliminate the effects of inflation using China’s annual consumer price index. Results The direct medical expenditure for lung cancer care (in 2011) was 39,015 CNY (US$6,041) per case, with an annual growth rate of 7.55% from 2002 to 2011. Drug costs were the highest proportionally in the total medical expenditure (54.27%), followed by treatment expenditure (14.32%) and surgical expenditure (8.10%). Medical expenditures for the disease varied based on region, hospital level, type, and stage. Conclusion The medical expenditure for lung cancer care is substantial in China. Drug costs and laboratory test are the main factors increasing medical costs.

Lung Cancer-Specific Mortality Risk and Public Health Insurance: A Prospective Cohort Study in Chongqing, Southwest China

“…Once discovered, most patients (62%) have basically reached the advanced stage of lung cancer. Studies have shown that more than 90% of the total medical expenses occur in the year after the diagnosis of lung cancer, and long-term treatment will not only have bad results but also bring a heavy financial burden (23,24). According to the characteristics of the population in my country, high-risk groups of lung cancer should undergo low-dose computed tomography screening every year, and positron emission tomography/computed tomography screening methods are not recommended.…”

Catastrophic health expenditure and its determinants in households with lung cancer patients in China: a retrospective cohort study

“…Therefore, it is recommended for future studies to recruit a larger sample. Fourth, the severity of lung cancer is also the impact factor of financial burden [ 32 ]. In the future, we will take into account variables related to disease severity such as cancer staging and treatment methods to explore the influencing factors of CHE in a more comprehensive manner.…”

Evolutionary game analysis of indoor radon mitigation with local government involvement

“…A previous survey indicated that the direct cost of lung cancer treatment in China is approximately 80,786 CNY [ 48 ]. We assumed that 60% of the costs are borne by local governments through medical insurance.…”